{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:02:42Z","timestamp":1767650562294},"reference-count":30,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","europeanneuropsychopharmacology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.euroneuro.2016.09.638","type":"journal-article","created":{"date-parts":[[2016,10,16]],"date-time":"2016-10-16T06:26:56Z","timestamp":1476599216000},"page":"2011-2017","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Paliperidone palmitate: factors predicting continuation with treatment at 2 years"],"prefix":"10.1016","volume":"26","author":[{"given":"David M.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Sparshatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"O\u2019Hagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olubanke","family":"Dzahini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2016.09.638_bib1","unstructured":"Akaike, H., 1973. Information theory and an extension of the maximum likelihood principle In: Petrov, B.N., Casaki, F. (Eds.),\u00a02nd International Symposium on Information Theory, Akademiai Kiado Budapest, pp. 267\u2013281."},{"key":"10.1016\/j.euroneuro.2016.09.638_bib2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/acps.12201","article-title":"Paliperidone palmitate long-acting injection\u2014prospective year-long follow-up of use in clinical practice","volume":"130","author":"Attard","year":"2014","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2016.09.638_bib3","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/FTD.0b013e3182577c43","article-title":"Risperidone and total 9-hydroxyrisperidone in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 2002\u20132010","volume":"34","author":"Bowskill","year":"2012","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.euroneuro.2016.09.638_bib4","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/2045125314540297","article-title":"The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal","volume":"4","author":"Brissos","year":"2014","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.09.638_bib5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/YIC.0b013e3282fce651","article-title":"Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone","volume":"23","author":"Canuso","year":"2008","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.09.638_bib6","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2165\/11208640-000000000-00000","article-title":"Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia","volume":"72","author":"Carter","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.euroneuro.2016.09.638_bib7","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.pnpbp.2010.08.012","article-title":"Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics","volume":"34","author":"Chen","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.09.638_bib8","series-title":"Modelling Survival Data in Medical Research","author":"Collett","year":"2015"},{"key":"10.1016\/j.euroneuro.2016.09.638_bib9","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"key":"10.1016\/j.euroneuro.2016.09.638_bib10","series-title":"ECDEU Assessment Manual for Psychopharmacology Rev Ed","first-page":"157","article-title":"The clinical global impressions scale","author":"Guy","year":"1976"},{"key":"10.1016\/j.euroneuro.2016.09.638_bib11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/YIC.0b013e3280c28424","article-title":"The attitude of patients towards antipsychotic depot treatment","volume":"22","author":"Heres","year":"2007","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.09.638_bib12","doi-asserted-by":"crossref","first-page":"23s","DOI":"10.1177\/088740341305805s04","article-title":"A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part II-physician perspectives","volume":"58","author":"Iyer","year":"2013","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.09.638_bib13","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1176\/appi.ajp.160.6.1125","article-title":"Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic","volume":"160","author":"Kane","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.09.638_bib14","doi-asserted-by":"crossref","first-page":"957","DOI":"10.4088\/JCP.13r08440","article-title":"Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies","volume":"74","author":"Kishimoto","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.09.638_bib15","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/schbul\/sbs150","article-title":"Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials","volume":"40","author":"Kishimoto","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2016.09.638_bib16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.schres.2010.11.020","article-title":"Oral versus depot antipsychotic drugs for schizophrenia\u2014a critical systematic review and meta-analysis of randomised long-term trials","volume":"127","author":"Leucht","year":"2011","journal-title":"Schizophr. Res."},{"issue":"Suppl.","key":"10.1016\/j.euroneuro.2016.09.638_bib17","first-page":"S5","article-title":"Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity","volume":"55","author":"Leysen","year":"1994","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.09.638_bib18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/2045125314558054","article-title":"Reducing the rates of prescribing high-dose antipsychotics and polypharmacy on psychiatric inpatient and intensive care units: results of a 6-year quality improvement programme","volume":"5","author":"Mace","year":"2015","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.09.638_bib19","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/schbul\/sbm033","article-title":"Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone","volume":"33","author":"Olfson","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2016.09.638_bib20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/JCP.0b013e3181dd3103","article-title":"A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia","volume":"30","author":"Pandina","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.09.638_bib21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1017\/S0033291702006797","article-title":"Psychiatrists\u05f3 attitudes to maintenance medication for patients with schizophrenia","volume":"33","author":"Patel","year":"2003","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2016.09.638_bib22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.schres.2006.11.015","article-title":"The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia","volume":"90","author":"Remington","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2016.09.638_bib23","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/ije\/28.5.964","article-title":"The use of fractional polynomials to model continuous risk variables in epidemiology","volume":"28","author":"Royston","year":"1999","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.euroneuro.2016.09.638_bib24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.schres.2011.06.016","article-title":"Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone","volume":"132","author":"Sliwa","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2016.09.638_bib25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1600-0447.2009.01352.x","article-title":"Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use","volume":"120","author":"Taylor","year":"2009","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2016.09.638_bib26","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/YIC.0000000000000028","article-title":"Long-acting paliperidone palmitate - interim results of an observational study of its effect on hospitalization","volume":"29","author":"Taylor","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.09.638_bib27","doi-asserted-by":"crossref","first-page":"196","DOI":"10.4088\/JCP.08m04427","article-title":"Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice","volume":"70","author":"Taylor","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.09.638_bib28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eurpsy.2016.04.009","article-title":"Effect of paliperidone palmitate on hospitalisation in a naturalistic cohort \u2013 a four-year mirror image study","volume":"37","author":"Taylor","year":"2016","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.09.638_bib29","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1017\/S1461145705006309","article-title":"Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome","volume":"9","author":"Taylor","year":"2006","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.09.638_bib30","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/JCP.0000000000000385","article-title":"Effectiveness and predictors of continuation of paliperidone palmitate long-acting injection treatment: a 12-month naturalistic cohort study","volume":"35","author":"Whale","year":"2015","journal-title":"J. Clin. Psychopharmacol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X16308343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X16308343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T15:59:03Z","timestamp":1536335943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X16308343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0924977X16308343"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2016.09.638","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paliperidone palmitate: factors predicting continuation with treatment at 2 years","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2016.09.638","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}